In 2025, Concerta, which contains the active ingredient methylphenidate, is prescribed primarily to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents, and adults. The starting dose for children is generally 18 mg once daily in the morning, with dosage adjustments based on patient response and tolerance. The maximum daily dose varies by age, with adults and teens typically not exceeding 72 mg per day.

Prescribing Concerta requires a detailed medical evaluation by a licensed healthcare provider, including assessment of heart health, family history of tic disorders, and monitoring during treatment. It is classified as a Schedule II controlled substance due to its potential for abuse and dependence, meaning valid prescriptions and careful patient monitoring are mandatory.

Due to ongoing supply issues, there may be limited stock availability for Concerta in certain regions, with authorities implementing temporary exemptions and usage guidelines until shortages resolve. Patients requiring Concerta may experience prescription limits or need to consult healthcare providers for alternative ADHD treatments.

Concerta should be taken once daily in the morning without crushing or chewing the tablets to maintain extended-release properties, and ongoing follow-up with providers is important for dosage and efficacy assessment.

In summary, limited stock of Concerta in 2025 can be managed through licensed prescriptions based on regulatory guidelines with proper evaluation and adherence to dosage limits to ensure safe and effective ADHD treatment.